10/18/2012 9:43:25 AM
NOKOMIS, Fla.--(BUSINESS WIRE)--Rainbow BioSciences, the biotech division of Rainbow Coral Corp. (OTCBB: RBCC), announced today that it has prepared a joint venture term sheet for presentation to Amarantus BioSciences (OTCBB: AMBS), the makers of a revolutionary new diagnostic platform for Parkinson’s disease. If the term sheet is approved by Amarantus, both parties will move forward with a joint venture agreement as soon as possible, said RBCC CEO Patrick Brown. The first project planned for the joint venture will be the commercialization of NuroPro, a sophisticated new test developed to more accurately and easily diagnose Parkinson’s disease. NuroPro works by identifying differentiated levels proteins and peptides in the blood of patients who have the disease.
comments powered by